PAYO vs. MEDP, FOUR, HQY, BILI, WPP, LYFT, MARA, SEZL, AMTM, and ETSY
Should you be buying Payoneer Global stock or one of its competitors? The main competitors of Payoneer Global include Medpace (MEDP), Shift4 Payments (FOUR), HealthEquity (HQY), Bilibili (BILI), WPP (WPP), Lyft (LYFT), Marathon Digital (MARA), Sezzle (SEZL), Amentum (AMTM), and Etsy (ETSY). These companies are all part of the "business services" industry.
Payoneer Global vs. Its Competitors
Payoneer Global (NASDAQ:PAYO) and Medpace (NASDAQ:MEDP) are both mid-cap business services companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings, institutional ownership and media sentiment.
Medpace has a net margin of 19.31% compared to Payoneer Global's net margin of 11.32%. Medpace's return on equity of 54.36% beat Payoneer Global's return on equity.
Payoneer Global presently has a consensus target price of $10.44, indicating a potential upside of 56.72%. Medpace has a consensus target price of $344.82, indicating a potential upside of 10.27%. Given Payoneer Global's stronger consensus rating and higher possible upside, research analysts clearly believe Payoneer Global is more favorable than Medpace.
82.2% of Payoneer Global shares are owned by institutional investors. Comparatively, 78.0% of Medpace shares are owned by institutional investors. 2.6% of Payoneer Global shares are owned by insiders. Comparatively, 20.3% of Medpace shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Medpace has higher revenue and earnings than Payoneer Global. Payoneer Global is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.
In the previous week, Medpace had 18 more articles in the media than Payoneer Global. MarketBeat recorded 22 mentions for Medpace and 4 mentions for Payoneer Global. Payoneer Global's average media sentiment score of 1.24 beat Medpace's score of 0.98 indicating that Payoneer Global is being referred to more favorably in the media.
Payoneer Global has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500. Comparatively, Medpace has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500.
Summary
Medpace beats Payoneer Global on 11 of the 17 factors compared between the two stocks.
Get Payoneer Global News Delivered to You Automatically
Sign up to receive the latest news and ratings for PAYO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PAYO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Payoneer Global Competitors List
Related Companies and Tools
This page (NASDAQ:PAYO) was last updated on 7/16/2025 by MarketBeat.com Staff
Free PAYO Stock Alerts